Labcorp
Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Alert:
Labcorp COVID-19 Antibody Testing Available Nationwide Learn more >>>
Synonyms
- Anti-HAV, IgM
- Antibody to Hepatitis A Virus, IgM
- HAVAb, IgM
Special Instructions
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Expected Turnaround Time
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.4 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube
Collection
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube; grossly hemolyzed specimens
|
Non-EDTA plasma specimen; PST gel-barrier tube |
|
Non-EDTA plasma specimen; PST gel-barrier tube; grossly hemolyzed specimens |
Test Details
Use
This assay is intended for use as an aid in the diagnosis of acute or recent infection (usually 6 months or less) with hepatitis A virus (HAV). This is an in vitro diagnostic immunoassay for the qualitative determination of IgM response to HAV. The presence of IgM antibody to HAV is diagnostic of acute HAV infection.
|
|
|
This assay is intended for use as an aid in the diagnosis of acute or recent infection (usually 6 months or less) with hepatitis A virus (HAV). This is an in vitro diagnostic immunoassay for the qualitative determination of IgM response to HAV. The presence of IgM antibody to HAV is diagnostic of acute HAV infection. |
Limitations
This assay has not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, or patients less than 2 years of age.
|
|
|
This assay has not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, or patients less than 2 years of age. |
Methodology
Immunochemiluminometric assay (ICMA)
Reference Interval
Negative
Additional Information
Hepatitis A virus (HAV) is a picornavirus primarily transmitted via the fecal-oral route. HAV replicates in the liver and is shed in high concentrations in feces from 2-3 weeks before to 1 week after the onset of clinical illness. IgM antibody develops within a week of symptom onset, peaks around three months, and is usually no longer detectable after six months. Many cases of HAV are subclinical, particularly in children. Antibody produced in response to HAV infection persists for life and confers protection against reinfection. The presence of IgM antibody to HAV is diagnostic of acute HAV infection. A positive test for total anti-HAV indicates immunity to HIV infection but does not differentiate current from previous HAV infection. Although usually not sensitive enough to detect the low level of protective antibody after vaccination, anti-HAV tests also might be positive after hepatitis A vaccination.
References
Giacoia GP, Kasprisin DO. Transfusion-acquired hepatitis A. South Med J. 1989 Nov;82(11):1357-1360.2683125
Lee HS, Vyas GN. Diagnosis of viral hepatitis. Clin Lab Med. 1987 Dec;7(4):741-757.3319367
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815
|
Giacoia GP, Kasprisin DO. Transfusion-acquired hepatitis A. South Med J. 1989 Lee HS, Vyas GN. Diagnosis of viral hepatitis. Clin Lab Med. 1987; 7(4):741-757 (review). 3319367 |
|
Giacoia GP, Kasprisin DO. Transfusion-acquired hepatitis A. South Med J. 1989 Nov;82(11):1357-1360.2683125 Lee HS, Vyas GN. Diagnosis of viral hepatitis. Clin Lab Med. 1987 Dec;7(4):741-757.3319367 Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815 |
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 006734 | Hep A Ab, IgM | 13950-1 | 006734 | Hep A Ab, IgM | 13950-1 |
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf